Top Markets
Coin of the day
PT Millennium Pharmacon International Tbk PT Millennium Pharmacon International Tbk

PT Millennium Pharmacon International Tbk

SDPC
Classificação em ações #31198
PT Millennium Pharmacon International Tbk is an Indonesian enterprise... PT Millennium Pharmacon International Tbk is an Indonesian enterprise specializing in the wholesale and provision of a diverse range of healthcare products. This includes both prescription and over-the-counter medicines, nutritional supplements, and medical equipment. The company's comprehensive distribution channels extend to various points of sale, such as retail pharmacies, hospitals, supermarkets, and other retail establishments. As of December 31, 2021, it managed 33 regional offices strategically located across Indonesia's major islands, including Java, Bali, Sumatera, Kalimantan, and Sulawesi. Founded in 1952, the organization was originally known as PT NVPD Soedarpo Corporation Tbk before adopting its current designation, PT Millennium Pharmacon International Tbk, in February 1990. Its corporate headquarters are situated in Jakarta Selatan, Indonesia, and it operates as a subsidiary of Pharmaniaga International Corporation Sdn. Bhd.
Preço da ação
$0.01099489
Valor de mercado
$14.01M
Variação (1 dia)
0.00%
Variação (1 ano)
37.04%
País
ID
Negociar PT Millennium Pharmacon International Tbk (SDPC)

Categoria

Lucros da PT Millennium Pharmacon International Tbk (SDPC)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da PT Millennium Pharmacon International Tbk, os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da PT Millennium Pharmacon International Tbk de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
$6.46B -
US
- -
US
$2.17B -
US
- -
US
$358.16M -
AU